Scotiabank analyst Sung Ji Nam initiated coverage of Adaptive Biotechnologies with an Outperform rating and $15 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Adaptive Biotechnologies upgraded to Overweight from Neutral at Piper Sandler
- Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting